FILING STATUS

Prolia^® is approved in the European Union*, United States, Australia, Switzerland and Canada.

In the United States and Canada, Prolia^® will be commercialized by Amgen only.

This website contains forward-looking statements based on Amgen's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K filed with the U.S. Securities & Exchange Commission for additional information on such risks and uncertainties.

USAGE

This website is intended to provide healthcare professionals outside of the United States and Canada with information about Prolia^®. This website may also contain other information about a particular country that may not be applicable or available in other countries.

Unless otherwise specified, all product names appearing in this Internet website are trademarks owned by or licensed to Amgen or GSK, or their subsidiaries or affiliates. No use of any Amgen or GSK trademark, trade name or trade dress in this website may be made without the prior written authorisation of Amgen or GSK.